PMID- 36401433
OWN - NLM
STAT- MEDLINE
DCOM- 20221122
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 46
DP  - 2022 Nov 18
TI  - General anesthesia, using remimazolam, for the patient with myelin 
      oligodendrocyte glycoprotein antibody associated disease (MOGAD): A case report.
PG  - e31734
LID - 10.1097/MD.0000000000031734 [doi]
LID - e31734
AB  - RATIONALE: Myelin oligodendrocyte glycoprotein antibody associated disease 
      (MOGAD) is one of auto-immune demyelinating diseases of nervous system. Although 
      both regional anesthesia and general anesthesia has been successfully performed 
      in the patient with demyelinating diseases of nervous system, it has been 
      controversial which one is better. PATIENT CONCERNS: Forty-four male patient was 
      admitted for arthroscopic elbow surgery due to limitation of range of motion. The 
      patient was diagnosed as MOGAD with anti-N-methyl-D-aspartate (NMDA) receptor 
      encephalitis, and steroid was used to prevent and treat symptoms and signs. 
      DIAGNOSIS: He was diagnosed as MOGAD with anti-NMDA receptor encephalitis, 1 year 
      ago. The patient complaint of dizziness, diplopia, nausea, vomiting, seizure, 
      general weakness and so on when he was confirmed as MOGAD with anti-NMDA receptor 
      encephalitis. The diagnosis of MOGAD was confirmed with positive anti-myelin 
      oligodendrocyte glycoprotein (MOG) Immunoglobulin (Ig)G and negative 
      anti-aquaporin 4 (AQP4) IgG in the blood. INTERVENTIONS AND OUTCOMES: After 
      steroid cover, total intravenous anesthesia (TIVA) with remimazolam and 
      remifentanil was established for the patients. Rocuronium was administered under 
      monitoring of neuromuscular blockade, using train of 4 (TOF). The operation was 
      performed without any event under right lateral decubitus position. The patient 
      was uneventfully recovered from anesthesia. LESSONS: The case report showed total 
      intravenous anesthesia with remimazolam and remifentanil under proper monitoring 
      was successfully performed in the patient with MOGAD.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Hong, Seung-Wan
AU  - Hong SW
AD  - Department of Anesthesiology and Pain Medicine, Konkuk University Medical Center, 
      Konkuk University School of Medicine, Seoul, Korea.
FAU - Kim, Byung-Soo
AU  - Kim BS
AD  - Department of Anesthesiology and Pain Medicine, Konkuk University Medical Center, 
      Konkuk University School of Medicine, Seoul, Korea.
FAU - Park, Sang-Tae
AU  - Park ST
AD  - Department of Anesthesiology and Pain Medicine, Konkuk University Medical Center, 
      Konkuk University School of Medicine, Seoul, Korea.
FAU - Jeong, Hae-Chang
AU  - Jeong HC
AD  - Department of Anesthesiology and Pain Medicine, Konkuk University Medical Center, 
      Konkuk University School of Medicine, Seoul, Korea.
FAU - Hwang, Min-Sik
AU  - Hwang MS
AD  - Department of Anesthesiology and Pain Medicine, Konkuk University Medical Center, 
      Konkuk University School of Medicine, Seoul, Korea.
FAU - Kim, Seong-Hyop
AU  - Kim SH
AUID- ORCID: 0000-0001-7764-9818
AD  - Department of Anesthesiology and Pain Medicine, Konkuk University Medical Center, 
      Konkuk University School of Medicine, Seoul, Korea.
AD  - Department of Infection and Immunology, Konkuk University School of Medicine, 
      Seoul, Korea.
AD  - Department of Medicine, Institute of Biomedical Science and Technology, Konkuk 
      University School of Medicine, Seoul, Korea.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 7V4A8U16MB (remimazolam)
RN  - P10582JYYK (Remifentanil)
RN  - 0 (Autoantibodies)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
SB  - IM
MH  - Male
MH  - Humans
MH  - *Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis/drug therapy
MH  - Remifentanil
MH  - Autoantibodies
MH  - Myelin-Oligodendrocyte Glycoprotein
MH  - Anesthesia, General
MH  - *Demyelinating Diseases
MH  - Oligodendroglia
PMC - PMC9678535
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2022/11/20 06:00
MHDA- 2022/11/23 06:00
PMCR- 2022/11/18
CRDT- 2022/11/19 01:04
PHST- 2022/11/19 01:04 [entrez]
PHST- 2022/11/20 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2022/11/18 00:00 [pmc-release]
AID - 00005792-202211180-00073 [pii]
AID - 10.1097/MD.0000000000031734 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Nov 18;101(46):e31734. doi: 
      10.1097/MD.0000000000031734.